Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

NCT00188721 | Completed

• 2 other identifiers: UHNREB#03-0462-CEHC#96142
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 2

Brief Summary

This study aims to evaluate if a light based technique, called Transillumination Breast Spectroscopy (TIBS), can be used to construct a non-invasive breast cancer risk predictor which provides a better odds ratio than mammographic parenchymal density.

Conditions

Breast Cancer

Keywords

Breast Cancer Risk; Optical Transillumination Spectroscopy; Transillumination Breast Spectroscopy

Study Arms (2)

1

Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)

2

Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.

Eligibility Criteria

• Age: 30 Years - 70 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Cases and controls recruited from the Breast Imaging Clinic at Princess Margaret Hospital or the Marvelle Koffler Centre at Mount Sinai Hospital (Toronto, Ontario, Canada)

You may qualify if:

• Are in good health and capable of providing consent
• Are willing to come in to the Princess Margaret Hospital for a single visit to meet with a female research assistant

You may not qualify if:

• Have had breast augmentation or reduction
• Have a personal history of breast cancer
• Have had a previous bilateral fine needle aspiration or core biopsy
• Have a breast tattoo

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (2)

Ontario Cancer Institute, Princess Maraget Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

Ontario Cancer Institute, Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

Related Publications (4)

• Blyschak K, Simick M, Jong R, Lilge L. Classification of breast tissue density by optical transillumination spectroscopy: optical and physiological effects governing predictive value. Med Phys. 2004 Jun;31(6):1398-414. doi: 10.1118/1.1738191.

  PMID: 15259643 BACKGROUND

• Simick MK, Jong R, Wilson B, Lilge L. Non-ionizing near-infrared radiation transillumination spectroscopy for breast tissue density and assessment of breast cancer risk. J Biomed Opt. 2004 Jul-Aug;9(4):794-803. doi: 10.1117/1.1758269.

  PMID: 15250768 BACKGROUND

• Blackmore KM, Knight JA, Jong R, Lilge L. Assessing breast tissue density by transillumination breast spectroscopy (TIBS): an intermediate indicator of cancer risk. Br J Radiol. 2007 Jul;80(955):545-56. doi: 10.1259/bjr/26858614. Epub 2007 May 30.

  PMID: 17537757 BACKGROUND

• Simick MK, Lilge L. Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk. Br J Radiol. 2005 Nov;78(935):1009-17. doi: 10.1259/bjr/14696165.

  PMID: 16249602 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Lothar Lilge, PhD

  Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada M5G 2M9; Department of Biophysics and Bioimaging, University of Toronto, Toronto, Ontario, Canada M5G 2M9

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 9, 2005
• First Posted: September 16, 2005
• Study Start: July 1, 2006
• Primary Completion: March 1, 2009
• Study Completion: September 1, 2009
• Last Updated: August 12, 2011

Record last verified: 2011-08

Locations

CA (2)